A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.

Trial Details

NCT ID
NCT07389239
Phase
PHASE1 / PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Decitabine
  • Cyclophosphamide Conditioning
  • NY-ESO-1 TCR/ dnTGFβRII
  • Aldesleukin
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Adult subjects (18 years and older) with histologically or cytologically of advanced (metastatic or inoperable) advanced solid tumors.
  • Tumor (either an archival specimen or a fresh biopsy) shows NY-ESO-1 expression of 1+ by IHC (H-score). NY-ESO-1 expression must be confirmed by ce…
  • Patients with NY-ESO-1 expressing solid tumors will be included. Patients must have received, been intolerant of, or been ineligible to receive at …
  • Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →